- Acquisition: Exponent Private Equity invests in the specialist of technical services dedicated to gas turbines OFS.
- Exit: The AI governance and compliance platform Velatir raises €5 million.
- Acquisition: The AI platform dedicated to training Guideless raises €1 million.
- Exit: BioMarin Pharmaceutical acquires the biotechnology company Alesta Therapeutics.
EXPONENT PRIVATE EQUITY
Acquisition: Exponent Private Equity invests in the specialist of technical services dedicated to gas turbines OFS
Exponent Private Equity makes an investment in OFS (formerly Oilfield Solutions) (Leinster / IRL), a technical services company specializing in rotating equipment and turbines, which provides installation, commissioning, operation and maintenance services, lifecycle management, training, and asset integrity to the power generation, renewable energy, offshore energy, and industrial sectors. This operation will allow OFS to accelerate its international development, strengthen its capabilities and workforce, and meet the growing demand for power generation infrastructure, particularly for data centers (Exponent Private Equity, press release)
SPINTOP VENTURES
Exit: The AI governance and compliance platform Velatir raises €5 million
Velatir (Region of Southern Denmark / DNK), a governance and compliance platform for AI that enables companies to monitor AI usage, control risks, and ensure human oversight, raises €5 million in a seed funding round co-led by Spintop Ventures and Ugly Duckling Ventures, with participation from Norrsken Evolve and business angels. Export and Investment Fund of Denmark (EIFO) complements this funding through a matching loan. The company will use these funds to accelerate its expansion in Europe and recruit new talent (Spintop Ventures, press release)
SUPERHERO CAPITAL
Acquisition: The AI platform dedicated to training Guideless raises €1 million
Guideless (Dzukija / LTU), a SaaS AI platform that transforms software workflows into interactive and automatically narrated video guides, aimed particularly at training, onboarding, and process documentation, raises €1 million in a pre-seed funding round led by Superhero Capital, with participation from Firstpick VC and business angels. The company already has over 3,000 users across 15 markets. This fundraising aims to accelerate product development, recruit new talent, and support its expansion in the United States, the United Kingdom, and Europe (Superhero Capital, press release)
THUJA CAPITAL
Exit: BioMarin Pharmaceutical acquires the biotechnology company Alesta Therapeutics
BioMarin Pharmaceutical (California / USA), a company that develops and commercializes drugs for genetically defined diseases such as achondroplasia and severe hemophilia A, as well as rare hereditary or lysosomal storage diseases, acquires Alesta Therapeutics (South Holland / NLD), a biotechnology company that develops innovative therapies targeting synthetic lethal metabolic dependencies in cancer. The existing shareholders of Alesta, including Frazier Life Sciences, Droia Ventures, Thuja Capital, Novartis Venture Fund, RTW Investments, RV Invest, and RTW Biotech Opportunities, are exiting the company’s capital. This acquisition allows BioMarin Pharmaceutical to address a larger market with significant unmet medical needs (Thuja Capital, press release)
